Study of Eltrombopag in Platelet Refractory Thrombocytopenia

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

August 31, 2010

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions
Thrombocytopenia
Interventions
DRUG

Eltrombopag

75 mg per day with possible dose escalation to 150 mg per day and 300 mg per day

Trial Locations (1)

45219

University of Cincinnati, Cincinnati

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

University of Cincinnati

OTHER

NCT01194167 - Study of Eltrombopag in Platelet Refractory Thrombocytopenia | Biotech Hunter | Biotech Hunter